As the prevalence of obesity, type 2 diabetes, and the opioid crisis in the United States continues to rise, so does chronic liver disease. From hepatitis C and hepatitis B to non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), liver disease affects a significant portion of the U.S. population. Hepatitis C virus (HCV) is a leading cause of cirrhosis, liver cancer, and mortality worldwide. Injection drug use, arising in conjunction with the opioid crisis, has contributed significantly to the increase in HCV infections. Chronic hepatitis B virus (HBV) remains a global epidemic, resulting in significantly increased morbidity and mortality. Furthermore, the rising number of obese and diabetic patients has resulted in the increased prevalence of NAFLD, which may progress to NASH in a large number of patients. To help clinicians and patients navigate the changing landscape of liver disease, we designed the Liver Disease Hub to provide resources and guidelines for screening, testing, and treatment of liver disease.

Our activities offer many credit types, including CME, AAFP Prescribed Credit, CNE, CPE, ABIM MOC, and ABP MOC. Each activity has been designed to meet the requirements for CME for MIPS. See each activity’s information page for the exact credit type and amount of credit offered.

Jump to:

 

Live & On-Demand Webcasts   CMEO Clinical Navigator   CMEO BriefCases   CMEOCast

 

Resources for Clinicians   Resources for Patients

Creating Action Steps for Linking Underserved Populations with Hepatitis C Care

 

Participate Now  

Hear expert insights on creating action steps to improve access to Hepatitis C care for patients within underserved populations in this upcoming CME Outfitters Live and OnDemand webcast. Expert faculty will discuss the many barriers to treating HCV in the injection drug use population, including stigma and established negative perceptions about people who inject drugs (PWID), with special attention paid to applying CDC universal screening guidelines to improve diagnosis and linkage to treatment, expanding treatment for HCV in primary care settings, and addressing disparities in HCV treatment initiation in underserved communities.

Test Your Knowledge: An Interactive Session on Emerging Data and Expert Insights on Hepatitis B

 

Participate Now  

Test your knowledge during this interactive CME Outfitters Live and OnDemand webcast featuring augmented reality animations that will reinforce the fibrotic consequence of untreated HBV. Data presentation and translation will showcase the importance of implementing routine screening protocols, optimizing efficacy and safety profiles of current agents when initiating or switching treatment, and routinely monitoring patients with HBV for disease progression HCC, and HBV reactivation.

Saturday Morning Coffee with Experts in NASH: What Is The Update?

 

Participate Now  

In this CME Outfitters webcast, a renowned panel of experts will highlight the underlying mechanisms of NASH via innovative augmented reality (AR) animations and present real-world case scenarios to share clinical insights on how to choose appropriate non-invasive diagnostic modalities, as well as translate latest data on emerging targeted therapies and their implications for clinical practice.

CMEO Clinical Navigator

Research You Can Use: Impact of the 2020 COVID-19 Pandemic on Ambulatory Hepatitis C Testing

 

Participate Now  

COVID-19 has presented many challenges for health care providers and hospital systems. In this edition of Research You Can Use, Dr. Gold reviews an article by Heather Sperring, MS, and colleagues from Boston Medical Center entitled, “Impact of the 2020 COVID-19 Pandemic on Ambulatory Hepatitis C Testing,” published in the Journal of Primary Care & Community Health, that outlines the negative impact of the pandemic on hepatitis C testing and the resulting consequences of the decrease in HCV identification.

Research You Can Use: Improving Outcomes of HCV Care Among Persons With Substance Use Disorders Treated in Co-Located Primary Care and Addiction Treatment Clinics

 

Participate Now  

There has been a marked increase in the incidence of hepatitis C virus (HCV) since 2010 due to the opioid epidemic and injection drug use among adults under age 30. Treating chronic HCV infection is straightforward due to the advent of direct-acting antivirals (DAAs), but populations with the highest prevalence, transmission, and reinfection rates have limited access to health systems and services.

This article focuses on improving outcomes of HCV care among persons with substance use disorders by explaining how clinicians can expand treatment in primary care settings and address disparities in HCV treatment initiation in underserved populations.

The HBV Refresher: Screen, Diagnose, Treat

 

Participate Now  

The first episode of this CMEOcast series on community-based efforts to improve screening and treatment of HBV will guide primary care clinicians through optimal strategies to screen for HBV in at-risk patients and utilize serological test results to drive guideline-directed care.

HBV Treatment Decision-Making

 

Participate Now  

In this second episode of the four-part CMEOCast Podcast to Practice series “Meeting Patients Where They Live: Community-Based Efforts to Improve Screening and Treatment of HBV,” faculty experts will discuss the efficacy and safety profiles of current agents for HBV, guiding clinicians through best practices when initiating or switching treatment. In addition, while there is currently no cure for HBV, considering the promise for the future, faculty experts will define “functional cure” for HBV and its application to agents in development.

Public Health Opportunities in the ED: Step 1: Screen for HBV, Step 2: Link to Care

 

Participate Now  

The third episode of this CMEOCast podcast series focuses on best practices for screening for HBV in the ED, incorporating the use of interprofessional teams, and fostering patient education for optimal treatment outcomes.

Long-Term Management of HBV: Meeting the Culturally Diverse Needs of Your Patient Community

 

Participate Now  

The final episode of this CME Outfitters podcast series aims to provide learners with strategies to provide culturally appropriate counseling and support services to high-risk populations in order to optimize retention and long-term HBV care.
CMEOBriefCase_logo

Throwing a Curve Ball at Hepatitis B Serological Tests: Interpreting and Applying Results to Guide Next Steps

 

Participate Now  

This CMEO BriefCase will introduce Samuel, a 54-year-old man with CHB, who presents to his health care professional with abdominal pain, back pain, vomiting, and fatigue. Join Dr. Kowdley as he dives deeper into a potential curve ball in Samuel’s laboratory test results.

Taking the Long View: Medical Comorbidities that May Shift Treatment Decision-Making

 

Participate Now  

This CME Outfitters BriefCase introduces Khadi, a 58-year-old woman who recently immigrated to the United States from Ghana and presents to her primary care provider for a new patient examination. This case will show how to optimize efficacy and safety profiles of current agents when initiating or switching treatment in patients with HBV.

Critical Steps for Long-Term Management of HBV: Focus on Monitoring and HBV Reactivation

 

Participate Now  

In this CME Outfitters BriefCase you meet Thomas, a 31-year-old man who immigrated from Nigeria as a child and has been diagnosed with CD20-positive B-cell non-Hodgkin’s lymphoma. His case will be used to illustrate the importance of screening at-risk patients for HBV and routinely monitoring patients with HBV who are immunosuppressed every 6 months for disease progression, HCC, and HBV reactivation.

Resources for Clinicians

NASH Pathophysiology

In this video, Dr. Mazen Noureddin uses an augmented reality animation of the human liver to describe how nonalcoholic steatohepatitis (NASH) emerges.

Molecular Targets for Emerging Therapies for NASH

In this video, Dr. Mazen Noureddin uses an augmented reality animation of the human liver to review molecules that play key roles in NASH pathophysiology and have thus been identified as targets for the development of pharmacotherapies for NASH.

An Animated Tour of the Mechanisms of HBV

In this video, Dr. Kris Kowdley uses an augmented reality animation to discuss the mechanisms involved with hepatitis B viral infection of the liver. Click the closed caption button to select subtitles in Vietnamese, Chinese (traditional), Chinese (simplified), Hmong, or Korean.

An Examination of the Stages of Fibrosis (for Clinicians)

In this video, Dr. Kris Kowdley uses an augmented reality animation to discuss the stepwise process of fibrosis progression from one stage to another. Click the closed caption button to select subtitles in Vietnamese, Chinese (traditional), Chinese (simplified), Hmong, or Korean.

The Mechanisms of HBV-Induced Hepatocellular Carcinoma

In this video, Dr. Kris Kowdley uses an augmented reality animation to discuss the primary mechanisms by which hepatitis B virus is thought to promote liver cancer. Click the closed caption button to select subtitles in Vietnamese, Chinese (traditional), Chinese (simplified), Hmong, or Korean.

Resources for Patients

An Examination of the Stages of Fibrosis (for Patients)

In this video, Dr. Kris Kowdley uses an augmented reality animation to discuss the various stages of fibrosis and the impact on the liver during each stage. Click the closed caption button to select subtitles in Vietnamese, Chinese (traditional), Chinese (simplified), Hmong, or Korean.

A Brief Overview of the Types of Hepatitis (for Patients)

In this animation, Dr. Kris Kowdley discusses the three most common viruses that cause hepatitis (hepatitis A virus, hepatitis B virus, and hepatitis C virus) and how each is transmitted. Click the closed caption button to select subtitles in Vietnamese, Chinese (traditional), Chinese (simplified), Hmong, or Korean.

Discover additional accredited CME/CE activities and patient resources on the Virtual Education Hub.

Visit the Hub